Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study.
about
Use of Inotropic Agents in Treatment of Systolic Heart FailureSignaling effectors underlying pathologic growth and remodeling of the heartForce generation by kinesin and myosin cytoskeletal motor proteinsEnsemble force changes that result from human cardiac myosin mutations and a small-molecule effectorChallenges in acute heart failure clinical management: optimizing care despite incomplete evidence and imperfect drugsModelling sarcomeric cardiomyopathies in the dish: from human heart samples to iPSC cardiomyocytesTargeting the sarcomere to correct muscle functionPotential new drug treatments for congestive heart failure.Translation of Cardiac Myosin Activation with 2-deoxy-ATP to Treat Heart Failure via an Experimental Ribonucleotide Reductase-Based Gene TherapyCardiac myosin binding protein-C: a novel sarcomeric target for gene therapy2-Deoxy adenosine triphosphate improves contraction in human end-stage heart failure.Acute decompensated heart failure update.The novel cardiac myosin activator omecamtiv mecarbil increases the calcium sensitivity of force production in isolated cardiomyocytes and skeletal muscle fibres of the ratMolecular effects of the myosin activator omecamtiv mecarbil on contractile properties of skinned myocardium lacking cardiac myosin binding protein-CRelative bioavailability, food effect, and safety of the single-dose pharmacokinetics of omecamtiv mecarbil following administration of different modified-release formulations in healthy subjectsAAV6-mediated Cardiac-specific Overexpression of Ribonucleotide Reductase Enhances Myocardial Contractility.Pharmacological Strategies to Retard Cardiovascular AgingIncorporating development of a patient-reported outcome instrument in a clinical drug development program: examples from a heart failure program.Focal energy deprivation underlies arrhythmia susceptibility in mice with calcium-sensitized myofilaments.SERCA2a gene therapy in heart failure: an anti-arrhythmic positive inotrope.Hypertrophic and dilated cardiomyopathy: four decades of basic research on muscle lead to potential therapeutic approaches to these devastating genetic diseases.Developments in heart failure 2011.Inotropes for the management of acute heart failure patients with renal dysfunction. Still an option?Molecular targets of current and prospective heart failure therapies.What's new in the treatment of acute heart failure?Antagonist molecules in the treatment of anginaEnd-stage heart failure non-pharmacological therapy: recent advances in pacemakers, pressure monitors, pumps and other devices.Heart failure highlights in 2012-2013.Novel drug targets in clinical development for heart failure.Inotropes and inodilators for acute heart failure: sarcomere active drugs in focus.Novel drug mechanisms in development for heart failure.Serelaxin : a potential new drug for the treatment of acute heart failure.New medical therapies for heart failure.Omecamtiv mecarbil: a new cardiac myosin activator for the treatment of heart failure.Emerging Therapies for Acute and Chronic Heart Failure: Hope or Hype?Long-term intravenous inotropes in low-output terminal heart failure?From Bench to Bedside: New Approaches to Therapeutic Discovery for Heart FailureThe myosin activator omecamtiv mecarbil: a promising new inotropic agent.Cardiac Myosin Activators in Systolic Heart Failure: More Friend than Foe?Metabolic support for the heart: complementary therapy for heart failure?
P2860
Q26774435-793DCFCF-FC00-4AE8-B7DE-F609D3C354C5Q26825154-10C3A1C4-FC07-4373-BD60-F3483542079AQ26827691-B6B11FF8-0671-404B-A5D2-29B9AE95F111Q27320554-8D75B53C-A04F-4AF1-B474-B7F5F967A6D7Q28085736-56812F0B-2F1B-40D9-BE6F-C7FBA38BF6A6Q28255887-278FE16D-6A49-486A-9274-BC0854D8EA7EQ28260629-26A9D842-F625-4176-997F-95430AFD8C50Q30251531-3DC31E27-6876-45DE-81A7-93CEA0538A81Q33728779-7720672F-6AD4-45C9-A47E-4784FACA1513Q34755677-0363ADD8-99C9-4724-ACCB-3F94BBD6BE93Q34995668-67E8944E-2879-46BA-A436-348B348E62AAQ35139964-4417F1D1-68D8-4F6B-8736-F5ABA5AE735DQ36036237-8DBE13E7-BF72-410D-A40A-A0F9D6D82A16Q36341946-738C2989-448A-493F-AC6D-ADD7D8D4D55CQ36645693-C0819588-7DC9-4B12-8976-8ED3991E9085Q36756838-E84C1BCB-62D8-496D-943E-870D55033010Q36972415-CD3D477C-3CD6-47BC-8486-7B069F8B59E3Q37258267-E95CDD99-64DE-4A0D-B7E0-FB7E9A924B9BQ37363558-9920404A-E7D6-4FBD-9E3E-4138FF860E1DQ37418216-22577E0C-E0AA-464E-801E-120072BD6929Q37701056-18F606B3-FD8E-4847-B10F-D8678BE77286Q37995246-1A6BA1F4-BB9C-49F6-B281-D9A1D3369AE2Q38061473-DCDE5B49-A13E-4B06-8CB6-E2F60F9354D2Q38076688-025528B9-4F51-4326-AA39-B8150C152136Q38123740-A510BC24-8533-4411-A67C-CFFFA209D307Q38139089-BCC6BEC9-CC18-49CD-B4DA-2F34A4F7AE3DQ38179215-A2A1FC58-C921-4690-B85D-0E1BCAA8DDDAQ38182010-C51B3836-B0C5-473E-B122-05F010618780Q38202895-534543BC-3232-4F3C-A951-BB0FDA5E3C34Q38208442-702C92FC-F430-4B11-ADEE-7106B82DA5EAQ38209074-AB4E0EBA-3C5C-4090-8C7A-E0735B858327Q38215304-5AD2AF15-A031-4B63-8EF1-414F27F448E1Q38594785-C9A067F6-7C54-4629-A491-288B6AA31BBCQ38639973-CE7F7A90-BA95-4D2A-A699-D756DD197538Q38694200-49C3CEB3-C2C6-43BA-BF71-7B8B22782044Q38734731-0729F92A-3045-47B7-98F7-786462334EB8Q38780801-40C8ADA7-2AEB-4DB4-B944-0DA05C9A6800Q38870685-11CB7327-142B-4E92-BEFD-3D79F0AA5BC1Q38939243-08EB1AFB-2168-44EF-9D81-0864C22D1566Q38998576-D983B86B-E826-4E33-9541-22E1DBAE6B56
P2860
Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study.
description
2011 nî lūn-bûn
@nan
2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Dose-dependent augmentation of ...... ecarbil: a first-in-man study.
@ast
Dose-dependent augmentation of ...... ecarbil: a first-in-man study.
@en
Dose-dependent augmentation of ...... ecarbil: a first-in-man study.
@nl
type
label
Dose-dependent augmentation of ...... ecarbil: a first-in-man study.
@ast
Dose-dependent augmentation of ...... ecarbil: a first-in-man study.
@en
Dose-dependent augmentation of ...... ecarbil: a first-in-man study.
@nl
prefLabel
Dose-dependent augmentation of ...... ecarbil: a first-in-man study.
@ast
Dose-dependent augmentation of ...... ecarbil: a first-in-man study.
@en
Dose-dependent augmentation of ...... ecarbil: a first-in-man study.
@nl
P2093
P1433
P1476
Dose-dependent augmentation of ...... ecarbil: a first-in-man study.
@en
P2093
Andrew A Wolff
Cyril P Clarke
Fady I Malik
Jacqueline H Lee
John R Teerlink
Jonathan H Goldman
Khalil G Saikali
Lyndsey Elliott
Michael M Chen
Mohammad Reza Habibzadeh
P304
P356
10.1016/S0140-6736(11)61219-1
P407
P577
2011-08-01T00:00:00Z